Literature DB >> 2414909

Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3.

M Ferguson, D M Evans, D I Magrath, P D Minor, J W Almond, G C Schild.   

Abstract

A region of virus capsid protein VP1 located 89-100 amino acids from the N-terminus has been proposed to comprise a major antigenic site involved in the neutralization of poliovirus type 3. Synthetic peptides 10-18 amino acids in length, containing all or part of this sequence, were tested for their ability to induce antiviral antibodies. Rabbits, but not guinea pigs or mice, immunized with the most active peptide, developed hightitered, type-specific, neutralizing antibodies for a wide range of poliovirus type 3 strains. Consistent with the broad type specificity of the antibody response was the observation that amino acids 89-100 of VP1 are highly conserved among different poliovirus type 3 strains. This sequence thus appears to provide, at least in part, a molecular basis for serotype antigenic specificity. Individual amino acids from 93 to 98 within this sequence were shown to be important for the neutralization of virus by antipeptide sera by examination of the ability of the sera to neutralize laboratory-derived poliovirus type 3 mutants with known single amino acid substitutions in the proposed antigenic site.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2414909     DOI: 10.1016/0042-6822(85)90389-7

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340.

Authors:  R J Pither; C X Zhang; C Shiels; J Tarlton; S Finerty; A J Morgan
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

2.  Molecular basis for linkage of a continuous and discontinuous neutralization epitope on the structural polypeptide VP2 of poliovirus type 1.

Authors:  K J Wiegers; K Wetz; R Dernick
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

3.  Immunological aspects of virology. WHO Working Group.

Authors: 
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

4.  Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.

Authors:  B Blondel; R Crainic; O Fichot; G Dufraisse; A Candrea; D Diamond; M Girard; F Horaud
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

5.  Structural factors modulate the activity of antigenic poliovirus sequences expressed on hybrid hepatitis B surface antigen particles.

Authors:  F Delpeyroux; E Van Wezel; B Blondel; R Crainic
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

6.  Regions of poliovirus protein VP1 produced in Escherichia coli induce neutralizing antibodies.

Authors:  M E Hoatlin; O M Kew; M E Renz
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

7.  Vaccination against poliomyelitis: present possibilities and future prospects.

Authors:  J L Melnick
Journal:  Am J Public Health       Date:  1988-03       Impact factor: 9.308

8.  Presentation and immunogenicity of the hepatitis B surface antigen and a poliovirus neutralization antigen on mixed empty envelope particles.

Authors:  F Delpeyroux; N Peillon; B Blondel; R Crainic; R E Streeck
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

9.  Immunological aspects of the prevention of viral diseases. WHO Workshop.

Authors: 
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

10.  Characterization of neutralizing antibodies to bovine enterovirus elicited by synthetic peptides.

Authors:  M S Smyth; A Trudgett; E M Hoey; S J Martin; F Brown
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.